[1]江正辉, 黄志强, 董鸿.亚临床肝癌[M].北京:军事医学科学出版社, 2003∶101-102.
|
[2]武昌, 朱崇云, 李强.PHC患者血清AFP AFU SF联合检测的意义[J].临沂医学专科学校学报, 2005, 27 (04) ∶267-269.
|
[3]Niwa Y, Matsumura M, Shiratori Y, et al.Quantitation ofαfecto-protein and Albumin messenger RNAs in human hepatocellula carci-noma[J].Hepatology, 1996, 23 (6) ∶1384.
|
[4]滕春燕, 张冰, 张曙东.原发性肝癌组织中甲胎蛋白mRNA定量检测的临床意义[J].中国实验诊断学, 2005, 9 (5) ∶788-789.
|
[5]Semeniuk DJ, Biosmenu R, Tam J, et al.Evidence that immuno-suppression is an intrinsic property of alpha-fetoproteinmolecule[J].Adv Exp Med Biol, 1995, 383∶255-269.
|
[6]Meng WS, Butterfied LH, Ribas A, et al.Fine specificity analysisof an HLA-A2.1-restricted immunodominant T cell epitope de-rived from alpha-fetoprotein[J].Mol Immunol, 2000, 37 (16) ∶943-950.
|
[7]Mizejewski GJ.Alpha-fetoprotein structure and function:relevanceto isoforms, epitopes and conformational variants[J].Exp Biol Med, 201, 226 (5) ∶377-408.
|
[8]Gotsman I, Israeli D, Alper R, et al.Induction of immune tolerancetoward tumor-associated-antigen enables growth of human hepato-ma in mice[J].Int J Cancer, 2002, 97 (1) ∶52-57.
|
[9]Dudich E, Semenkova L, Gorbatova E, et al.Growth-regulativeactivity of human alpha-fetoprotein for different types of tumor andnormal cells[J].Tumor Biol, 1998, 19 (1) ∶30-40.
|
[10]Wang XW, Xie H.Alpha-feto protein enhanced the proliferationof huma hepatoma cells in vitro[J].Life Sci, 1999, 64 (1) ∶17-23.
|
[11]Nagata S.Fas lig and induced apoptosis[J].Annu Rev Genet, 1999, 33∶29-55.
|
[12]Nagao M, Nakajima Y, Kanehiro H, et al.The impact of interferongamma receptor expression on the mechanism of escape from host im-mune surveillance in hepatocellular carcinoma[J].Hepatology, 2000, 32 (3) ∶491-500.
|
[13]Grimm CF, Ortmann D, Mohr L, et al.Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinomaleads to tumor regression in mice[J].Gastroenterology, 2000, 119 (4) ∶1104-1112.
|
[14]Butterfield LH, Meng WS, Koh A, et al.T-Cell Responses toHLA-A2.1-Restricted Peptides Derived from Humanα-Fetoprotein[J].Immunology, 2001, 166∶5300-5308.
|
[15]Vollmer C, Eiber J, Butterfield L, et al.α-Fetoprotein-specificgenetic immunotherapy for hepatocellular carcinoma[J].Cancer Res, 1999, 59 (13) ∶3064-3067.
|
[16]Charles M, Vollmer J, Fritz C, et al.Alpha-Fetoprotein-specif-ic genetic immunotherapy for hepato cellular carcinoma[J].CancerRes, 1999, 59 (13) ∶3064-3067.
|
[17]张利旺, 张红梅, 贾军, 等.以AFP为靶点的肝癌树突状细胞免疫治疗的实验研究[J].现代肿瘤医学, 2005, 13 (6) ∶736-739.
|
[18]Kanai F, Lan K, Shiratori Y, et al.Invivo gene therapy for alpha-fetoprotein producing hepatocellular by adenovirus-mediated transferof cytosine deaminase gene[J].Cancer Res, 1997, 57 (3) ∶461-465.
|
[19]Kunitomi M, Takayama E, Suzuki S, et al.Selective inhibition ofhepatoma cells using diphtheria toxin A under the control of the pro-moter/enhancer region of the human alpha-fetoprotein gene[J].Jpn J Cancer Res, 2000, 91 (3) ∶343-345.
|
[20]李绍祥, 李瑞利, 凌昌全, 等.携蜂毒素基因重组腺病毒对HepG2细胞甲胎蛋白和基质金属蛋白酶-2表达的影响[J].河北医科大学学报, 2006, 27 (1) ∶10-14.
|